EVO vs PRQR
Evotec SE and ProQR Therapeutics N.v., side by side — 4 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | EVO | PRQR |
|---|---|---|
| Revenue | €797.0M | €15.9M |
| Net income | €-196.1M | €-42.2M |
| Gross margin | 14.4% | · |
| Net margin | −24.6% | −265.2% |
| Return on equity | −18.9% | −61.2% |
| Diluted EPS | −€1.11 | −€0.40 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | €-99.2M | €-53.8M |
| Equity | €952.5M | €49.4M |
| Net debt / equity | −0.02× | −1.77× |
| Current ratio | 1.98× | 3.09× |
| Revenue CAGR 5y | 12.3% | · |
| Profit CAGR 5y | · | · |
EVO bills 50.1× the revenue of PRQR, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
4 years side by side
| Fiscal year | EVO | PRQR |
|---|---|---|
| FY2024 | €797.0M | €18.9M |
| FY2023 | €781.4M | €6.5M |
| FY2022 | €751.4M | €3.6M |
| FY2021 | €618.0M | €1.3M |
Bottom line
| Fiscal year | EVO | PRQR |
|---|---|---|
| FY2024 | €-196.1M | €-27.8M |
| FY2023 | €-83.9M | €-28.1M |
| FY2022 | €-175.7M | €-64.4M |
| FY2021 | €215.5M | €-60.7M |
Standard deviation, each side
EVO's return on equity has been more volatile than PRQR's over the 6 comparable fiscal years — 13.3 percentage points of standard deviation against 10.1.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
EVO led in return on equity in every one of the 6 comparable fiscal years — a structural lead, not a recent swing.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.